Vaxcyte opened lower at $67.60, compared with its previous close of $68.62. In the last trading session, the stock traded between $65.00 and $67.74. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Vaxcyte is now worth
$ 251.09
Giving a profit of
$ 151.09 (151.09%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 9 Analysts
Buy
88.89%
Hold
11.11%
Sell
0%
Markets Today
Today's Change
$-3.94 (-5.74%)
Day High
$67.74
Day Low
$65.00
Day Open
$67.60
Prev Close
$68.62
Volume
8,24,648
1W Return
-1.48%
1M Return
-8.58%
3M Return
9.24%
6M Return
19.80%
1Y Return
41.66%
Fundamentals
Market Cap ($ Mn)
10,239
PE Ratio
-
PB Ratio
3.14
PEG Ratio
-
ROE
-25.29%
ROCE
-28.46%
EPS (TTM)
$-1.99
Investment Returns
1 Week
-1.48%
1 Month
-8.58%
3 Months
9.24%
6 Months
19.80%
9 Months
16.86%
Financials
Quarterly
All values in $ Mn
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
0.0
Sep 26
Updates
7Oct
Vaxcyte prices $1 billion offering at $64 per share for vaccine dev
Vaxcyte priced concurrent offerings totaling $1 billion. Equity sold at $64.00 per share with pre-funded warrants. $500 million in 1.50% convertible notes due 2032 issued. Proceeds fund VAX-31 Phase 3 trials and manufacturing scale-up.
1mo ago
5Oct
Vaxcyte says VAX-31 meets all primary endpoints in OPUS-1 Phase 3 trial
VAX-31 met all prespecified primary endpoints in OPUS-1 Phase 3 trial vs Prevnar 20/Capvaxive. All 28 shared serotypes in adults 50+ met noninferiority; unique serotypes showed superiority. Safety profile similar to PCV20 and PCV21 across all ages studied. Company plans Biologics License Application submission in first half of 2028.
1mo ago
28Aug
Vaxcyte management to host fireside chats at two healthcare conferences
Vaxcyte management to host fireside chats at Wells Fargo and Cantor Global Healthcare Conferences. Wells Fargo session scheduled for September 8, 2026 at 3:00 p.m. ET. Cantor Global session set for September 9, 2026 at 2:45 p.m. ET. Live webcasts available on company website for 30 days post-event.
Vaxcyte delivered Q2 EPS of $(1.97), beating the $(2.22) estimate by 11.26%, but losses surged 61.48% YoY from $(1.22).
3mo ago
9Jul
Vaxcyte management to attend July investor conferences
Vaxcyte, Inc. announced its management will host one-on-one meetings at the Leerink Partners Therapeutics Forum on July 15 and the BTIG Virtual Biotechnology Conference on July 28. The company's pipeline features VAX-31, a 31-valent pneumococcal conjugate vaccine in Phase 3 and Phase 2 trials, and VAX-24, a 24-valent candidate.
